TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$33.31
0.20 (0.62%)
▲
5d:
-3.85%
30d:
-3.32%
90d:
+7.57%
HOLD
MODERATE Confidence
Analysis Updated: Jul 9, 2026 12:00 AM ET
Earnings: Jul 29, 2026
18d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA is fairly valued with market pricing in 0.0% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: TEVA is fairly valued with market pricing in 0.0% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.16
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$39.84
16.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $33.30, which is considered slightly low relative to its 30-day fair value range of $32.78 to $34.50. The stock's valuation (Forward PE: 10.8) is in line with its historical norms (10.7). At these levels, the market is pricing in 0.0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a uptrend. The price is currently testing key support at $32.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.90 (+23.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is in a uptrend. The price is currently testing key support at $32.42. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TEVA has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $40.90 (+23.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$32.78 -
$34.50
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 23.6% below Wall St target ($40.90)
- NEUTRAL: Market pricing in 0.0% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$32.78 -
$34.50
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$32.42
Resistance Level
$35.47
Current Trend
Uptrend
Technical data as of
Jul 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.75
Wall Street Target
$40.90
(+23.6%)
Revenue Growth (YoY)
2.3%
Earnings Growth (YoY)
72.2%
Profit Margin
9.0%
PE vs Historical
10.8 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
0%
(market-implied from PE analysis)
1-Year Target
$33.10
(0%)
2-Year Target
$33.10
(0%)
3-Year Target
$33.10
(0%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
PE COMPRESSION
$32.95
(-1%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 38.6%)
$178.59
(+440%)
Base:
(SPY PE: 10.7, Growth: 38.6%)
$88.14
(+166%)
Bear:
(PE: 9.1, Growth: 38.6%)
$74.92
(+126%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 25.77 | Current EPS (TTM): $1.29
Bull Case
$73.13
(+121%)
Analyst growth 100.0%, PE expands to 28.3
Base Case
$66.48
(+101%)
Market implied 100.0%, PE stable at 25.8
Bear Case
$22.60
(-32%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 10, 2026 9:55 AM ET
Data refreshes hourly during market hours. Next update: 10:55 AM
Data refreshes hourly during market hours. Next update: 10:55 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
9
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$196 | 64 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$118 | 58 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 62 BUY |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 49 HOLD |
